figshare
Browse
12974_2021_2118_MOESM4_ESM.pdf (7.36 MB)

Additional file 4 of Pexidartinib treatment in Alexander disease model mice reduces macrophage numbers and increases glial fibrillary acidic protein levels, yet has minimal impact on other disease phenotypes

Download (7.36 MB)
journal contribution
posted on 2021-03-09, 04:41 authored by Michelle M. Boyd, Suzanne J. Litscher, Laura L. Seitz, Albee Messing, Tracy L. Hagemann, Lara S. Collier
Additional file 4: Additional Figure 4: Pexidartinib treatment does not impact expression of Plp1 and Mog. Legend: RT-qPCR for Plp1 for the olfactory bulb (a) and hippocampus (b), Mog for the olfactory bulb (c) and hippocampus (d). Statistical analyses: One-way ANOVA with Bonferroni’s post-test for the indicated comparisons, n.s. = non-significant (p>0.05). N = 5-6 per group.

Funding

National Institutes of Health Institute for Clinical and Translational Research, University of Wisconsin, Madison Eunice Kennedy Shriver National Institute of Child Health and Human Development

History

Usage metrics

    Journal of Neuroinflammation

    Categories

    Keywords

    PexidartinibCSF1RAlexander diseaseGFAPMacrophage

    Licence

    CC BY + CC0

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC